73 results
6-K
EX-99.1
SPRC
SciSparc Ltd
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
the Company’s recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling … involved in the clinical trial. This achievement represents a pivotal moment for SciSparc as we introduce SCI-210, an innovative cannabinoid-based treatment
6-K
EX-99.1
SPRC
SciSparc Ltd
29 Feb 24
Report of Foreign Private Issuer
9:07am
completed the manufacturing of and delivered its innovative SCI- 210 treatment, in accordance with its initiation of enrollment for the clinical trial
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
receptor type 2, or CB2 receptor, agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D … , along with funding for such research;
establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models
6-K
EX-99.1
SPRC
SciSparc Ltd
28 Nov 23
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
4:00pm
to develop safe and effective innovative therapies. The successful collaboration between SciSparc and Clearmind continues to demonstrate
6-K
EX-99.1
fg53gqch
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.1
3m4zwnwvm1kz4gfzp
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.2
l0dz0ee puv
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.2
i7pgq 3yt3ni6
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
ulp064
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
763hlut0olv
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
rft6f4rr6ehiys9e
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
m0bm2u35l cd7a
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
x9b1p
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.1
fyxmp
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.2
xmr0nv 4q788wy8
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
fdrpqu25n8969plfin1u
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.1
gf2ti6o8 35kdjrjm
9 Jun 22
SciSparc’s Board of Directors Provides Strategic Decision
8:38am
6-K
EX-99.1
tn99t5 p9ozave
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm